Backed by the combined expertise of three USC schools, scientists are developing a new drug aimed at a previously unexplored biological target in Alzheimer’s disease, aided by an $8 million grant from the National Institutes of Health. The team, led by Hussein Yassine of the Keck School of Medicine of USC, is investigating why some carriers of the APOE4 gene — the strongest genetic risk factor for Alzheimer’s — develop dementia while others remain cognitively healthy. His lab has identified an enzyme that predisposes the brain to inflammation and the research team is now working to find a drug that can block it without harmful side effects. Their work points to an enzyme which breaks down protective omega-3 fatty acids in the brain and triggers damaging inflammation.

A neuroimaging project led by Dr. Pedro Rosa-Neto at The Neuro (Montreal Neurological Institute-Hospital) of McGill University has received a major boost thanks to a $10-million grant from the Weston Family Foundation.

The funding is part of a $20-million initiative by the foundation to support highly ambitious scientific endeavors under its Healthy Aging Strategy, comprised of the Weston Brain Institute and the Weston Family Microbiome Initiative.

he approval of new antibody medications for Alzheimer's disease – lecanemab and donanemab – and diagnostic tests in the blood mark the beginning of a new era in Alzheimer's disease diagnosis and treatment. However, without rapid reform in healthcare systems, public policy, and societal attitudes, their potential will not be fully realised, argue 40 leading Alzheimer's disease experts in The Lancet Series on Alzheimer's disease.